Eprodisate API Manufacturers

compare suppliers & get competitive offers

teaser-1024x654-1
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Eprodisate is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Eprodisate or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Eprodisate API 21668-77-9?

Description:
Here you will find a list of producers, manufacturers and distributors of Eprodisate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Eprodisate 
Synonyms:
1,3-propanedisulfonic acid , Propane-1,3-disulfonate , Propane-1,3-disulfonic acid , Propane-1,3-disulphonate  
Cas Number:
21668-77-9 
DrugBank number:
DB06405 
Unique Ingredient Identifier:
6QFP76V7S7

General Description:

Eprodisate, identified by CAS number 21668-77-9, is a notable compound with significant therapeutic applications. Eprodisate slows the decline of renal function in AA amyloidosis.

Indications:

This drug is primarily indicated for: Investigated for use/treatment in amyloidosis. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Mechanism of Action:

Eprodisate functions by: Decline in renal function associated with Amyloid A (AA) amyloidosis can be slowed by eprodisate (Kiacta), a drug that inhibits the deposit of the complex protein in tissues. AA amyloidosis is a serious, frequently fatal disorder involving deposits of amyloid fibrils in various organs and tissues. It is a complication of many chronic inflammatory disorders, but little is known about its etiology or natural history. Eprodisate delays the progression of AA amyloidosis-associated renal disease. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Categories:

Eprodisate is categorized under the following therapeutic classes: Acids, Acids, Noncarboxylic, Alkanes, Hydrocarbons, Acyclic, Sulfur Acids, Sulfur Compounds. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.